Comerica Bank Sells 7,750 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Comerica Bank cut its Alnylam stake by 65.7%, selling 7,750 shares in Q4 and now holds 4,040 shares valued at about $1.61 million.
• Alnylam topped Q1 expectations with $1.99 EPS vs. $0.87 consensus and $1.17B revenue (up 96.4% YoY), and analysts carry an average price target near $472 with a "Moderate Buy" consensus.
• Significant trading activity: insiders sold 38,656 shares (roughly $12.37M) over the last three months, while institutional ownership remains high at 92.97%.

Comerica Bank reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 65.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,040 shares of the biopharmaceutical company's stock after selling 7,750 shares during the quarter. Comerica Bank's holdings in Alnylam Pharmaceuticals were worth $1,607,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ALNY. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $243,000. Geneos Wealth Management Inc. raised its stake in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 175 shares during the last quarter. Flow Traders U.S. LLC purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at $241,000. Daiwa Securities Group Inc. raised its stake in Alnylam Pharmaceuticals by 0.3% during the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company's stock valued at $4,220,000 after buying an additional 35 shares during the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 70,300.0% in the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company's stock worth $229,000 after purchasing an additional 703 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 2.3%

Shares of ALNY stock opened at $295.91 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The stock's 50 day simple moving average is $318.15 and its two-hundred day simple moving average is $372.43. Alnylam Pharmaceuticals, Inc. has a 1 year low of $245.96 and a 1 year high of $495.55. The company has a market cap of $39.51 billion, a PE ratio of 80.85 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company's revenue for the quarter was up 96.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.44) earnings per share. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.17 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an "equal weight" rating in a research note on Friday, May 1st. Truist Financial cut their price target on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating for the company in a report on Monday, April 13th. Weiss Ratings raised Alnylam Pharmaceuticals from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday. Wall Street Zen raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, May 2nd. Finally, Freedom Capital raised Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $471.96.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 2,242 shares of the firm's stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the transaction, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. This trade represents a 8.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,242 shares of the stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the sale, the executive vice president directly owned 59,802 shares in the company, valued at $18,543,404.16. This trade represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 38,656 shares of company stock worth $12,370,696 over the last three months. Corporate insiders own 0.86% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.